[Clinical evaluation of glipizide. Results of a multicentric study in Spain].

Abstract

In this study, with the evaluation of 621 diabetics under treatment, it is shown that glipizide is a potent oral sulfonilurea which controlled satisfactorily the blood sugar levels in 83,5% of diabetics without previous treatment, 67% of the cases with positive response to previous anti-diabetic therapy and 51,3% of the patients that had not responded to previous treatments. The most frecuently used dosage was 5 mg daily, with a minimum of 2,5 mg and a maximum of 30 mg. Tolerance and safety observed was excellent.